Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer

Published on Oct 6, 2021in The Journal of Pathology7.996
· DOI :10.1002/PATH.5813
Nanor Sirab1
Estimated H-index: 1
(PSL Research University),
Damien Drubay11
Estimated H-index: 11
(Université Paris-Saclay)
+ 15 AuthorsYves Allory59
Estimated H-index: 59
(UVSQ: Versailles Saint-Quentin-en-Yvelines University)
Sources
Abstract
Basal/squamous (Ba/Sq) subtype represents an intrinsic and robust group in the consensus molecular classification of muscle-invasive bladder cancer (MIBC), with poor outcome and controversial chemosensitivity. We aimed to investigate the spectrum of intratumor heterogeneity (ITH) in the Ba/Sq subtype. First, we validated a 29-gene NanoString CodeSet to predict the Ba/Sq subtype for FFPE samples. We identified heterogeneous Ba/Sq tumors in a series of 331 MIBC FFPE samples using dual GATA3/KRT5/6 immunohistochemistry (IHC). Heterogeneous regions with distinct immunostaining patterns were studied separately for gene expression using the 29-gene CodeSet, for mutations by targeted next-generation sequencing, and for copy number alteration (CNA) by microarray hybridization. Among 83 Ba/Sq tumors identified by GATA3/KRT5/6 dual staining, 19 tumors showed heterogeneity at the IHC level. In one third of the 19 cases, regions from the same tumor were classified in different distinct molecular subtypes. The mutational and CNA profiles confirmed the same clonal origin for IHC heterogeneous regions with possible subclonal evolution. Overall, two patterns of intratumoral heterogeneity (ITH) were observed in Ba/Sq tumors: low ITH (regions with distinct immunostaining, but common molecular subtype and shared CNA) or high ITH (regions with distinct immunostaining, molecular subtype, and CNA). These results showed multilayer heterogeneity in Ba/Sq MIBC. In view of personalized medicine, this heterogeneity adds complexity and should be taken into account for sampling procedures used for diagnosis and treatment choice. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
📖 Papers frequently viewed together
23 Authors (Jing Wang)
20196.64Cancers
13 Authors (Haider A. Mejbel, ..., Phyu P. Aung)
References41
Newest
Abstract Context This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To provide practical evidence-based recommendations and consensus statements on the clinical management of MMIBC with a focus on diagnosis and treatment. Evidence acquisition A broad and comprehensive scoping exercise covering all areas of the MMIBC guideline has been performed annually since its 2017 publication (based on the 2...
Source
#1Ann Taber (Aarhus University Hospital)H-Index: 5
#2Emil Christensen (Aarhus University Hospital)H-Index: 12
Last. Lars Dyrskjøt (Aarhus University Hospital)H-Index: 64
view all 14 authors...
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a comprehensive multi-omics analysis (genomics, transcriptomics, epigenomics and proteomics) of 300 MIBC patients treated with chemotherapy (neoadjuvant or first-line) to identify molecular changes associated with treatment response. DNA-based associat...
Source
#1Aurélie KamounH-Index: 3
Last. John N. Weinstein (University of Texas MD Anderson Cancer Center)H-Index: 129
view all 42 authors...
Abstract Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. Objective To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. Design, setting, and participants We used 1750 MIBC transcriptomic profiles from 16 published datasets and two a...
Source
#1Kunihiko Hinohara (Harvard University)H-Index: 22
#2Kornelia Polyak (Harvard University)H-Index: 110
Most human tumors are composed of genetically and phenotypically heterogeneous cancer cell populations, which poses a major challenge for the clinical management of cancer patients. Advances of single-cell technologies have allowed the profiling of tumors at unprecedented depth, which, in combination with newly developed computational tools, enable the dissection of tumor evolution with increasing precision. However, our understanding of mechanisms that regulate intratumoral heterogeneity and ou...
Source
#1Charles C. Guo (University of Texas MD Anderson Cancer Center)H-Index: 42
#2Tadeusz Majewski (University of Texas MD Anderson Cancer Center)H-Index: 17
Last. Bogdan Czerniak (University of Texas MD Anderson Cancer Center)H-Index: 68
view all 25 authors...
Summary Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conven...
Source
#1Joshua I. Warrick (PSU: Pennsylvania State University)H-Index: 17
#2Gottfrid Sjödahl (Lund University)H-Index: 21
Last. David J. DeGraff (PSU: Pennsylvania State University)H-Index: 19
view all 9 authors...
Molecular subtyping may inform on prognosis and treatment response in bladder cancer. However, intratumoral molecular heterogeneity is not well studied in this disease and could complicate efforts to use molecular subtyping to guide patient management. To investigate intratumoral heterogeneity in bladder cancer, we examined molecular subtypes in a consecutive, retrospective cystectomy series of histologic variant bladder cancers and conventional urothelial carcinomas co-occurring with them. Mole...
Source
#1Daniel H. HovelsonH-Index: 24
#2Aaron M. UdagerH-Index: 23
Last. Scott A. TomlinsH-Index: 88
view all 21 authors...
Abstract Background Integrated molecular profiling has identified intrinsic expression-based bladder cancer molecular subtypes. Despite frequent histological diversity, robustness of subtypes in paired conventional (urothelial) and squamous components of the same bladder tumor has not been reported. Objective To assess the impact of histological heterogeneity on expression-based bladder cancer subtypes. Design, setting, and participants We performed clinically applicable, targeted DNA and/or RNA...
Source
#1Gottfrid Sjödahl (Lund University)H-Index: 21
#2Pontus Eriksson (Lund University)H-Index: 16
Last. Mattias Höglund (Lund University)H-Index: 72
view all 9 authors...
Molecular subtypes of muscle-invasive bladder tumors have emerged as a promising research tool with potential to stratify patients for neoadjuvant treatment. Prior to radical cystectomy, the utility of molecular classification and biomarkers depend on concordance between tissue from transurethrally resected specimens and disseminated disease. We assess the concordance of molecular subtypes and a large number of potential biomarkers in 67 pairs of muscle-invasive bladder tumors and synchronous ly...
Source
#1Anissa MoktefiH-Index: 11
#2Damien Pouessel (University of Paris)H-Index: 21
Last. Yves Allory (Curie Institute)H-Index: 59
view all 12 authors...
Although human epidermal growth factor receptor 2 (HER2) may represent a therapeutic target, its evaluation in urothelial carcinoma of the bladder does not rely on a standardized scoring system by immunohistochemistry or fluorescent in situ hybridization (FISH), as reflected by various methodology in the literature and clinical trials. Our aim was to improve and standardize HER2 amplification detection in bladder cancer. We assessed immunohistochemical criteria derived from 2013 American Society...
Source
Summary We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the overall mutational load was associated with APOBEC-signature mutagenesis. Clustering by mutation signature identified a high-mutation subset with 75% 5-year survival. mRNA expression clustering refined prior clustering analyses and identified a poor-survival "neuronal" subtype in which the majority of tumors l...
Source
Cited By1
Newest
#1Etienne LavalleeH-Index: 1
#2John P. SfakianosH-Index: 27
Last. David J. MulhollandH-Index: 21
view all 3 authors...
Acquired therapeutic resistance remains a major challenge in cancer management and associates with poor oncological outcomes in most solid tumor types. A major contributor is tumor heterogeneity (TH) which can be influenced by the stromal; immune and epithelial tumor compartments. We hypothesize that heterogeneity in tumor epithelial subpopulations—whether de novo or newly acquired—closely regulate the clinical course of bladder cancer. Changes in these subpopulations impact the tumor microenvir...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.